Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Juliana Machado-Rugolo, Tabatha Gutierrez Prieto, Alexandre Todorovic Fabro, Edwin Roger Parra Cuentas, Vanessa Karen Sá, Camila Machado Baldavira, Claudia Aparecida Rainho, Erick C Castelli, Cecilia Farhat, Teresa Yae Takagaki, Maria Aparecida Nagai & Vera Luiza Capelozzi. (2021) Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort. Pharmacogenomics and Personalized Medicine 14, pages 239-252.
Read now
Read now
Weiwei Tang, Xiongxiong Pan, Di Han, Dawei Rong, Minghui Zhang, Lulu Yang, Jie Ying, Hua Guan, Ziyi Chen & Xuehao Wang. (2019) Clinical significance of CD8+ T cell immunoreceptor with Ig and ITIM domains+ in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy. OncoImmunology 8:6.
Read now
Read now
Articles from other publishers (11)
Shizhao Ma, Jinzhi Lei & Xiulan Lai. (2023) Modeling tumour heterogeneity of PD-L1 expression in tumour progression and adaptive therapy. Journal of Mathematical Biology 86:3.
Crossref
Crossref
Dinara A. Akhmetova, Vadim V. Kozlov & Ludmila F. Gulyaeva. (2022) New Insight into the Role of AhR in Lung Carcinogenesis. Biochemistry (Moscow) 87:11, pages 1219-1225.
Crossref
Crossref
Wenchao Yang, Bixia Xuan, Mengqi Chen, Xiaofang Li, Jiana He, Haiyan Si & Yefei Zhang. (2022) Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. Frontiers in Oncology 12.
Crossref
Crossref
Ziqi Ye, Wenchao Yang, Bixia Xuan, Xiaofang Li, Jiana He, Haiyan Si & Wenhua Ma. (2022) Efficacy and Safety Evaluation of Sintilimab for Cancer Treatment: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology 13.
Crossref
Crossref
James J. Saller & Theresa A. Boyle. (2022) Molecular Pathology of Lung Cancer. Cold Spring Harbor Perspectives in Medicine 12:3, pages a037812.
Crossref
Crossref
Javier FierroJr.Jr., Jake DiPasquale, Joshua Perez, Brandon Chin, Yathip Chokpapone, An M. Tran, Arabella Holden, Chris Factoriza, Nikhi Sivagnanakumar, Rocio Aguilar, Sarah Mazal, Melissa Lopez & Huanyu Dou. (2022) Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization. Scientific Reports 12:1.
Crossref
Crossref
Daniel A. SmithDavid PfauSree H. TirumaniFrancesco AlessandrinoNavid SadriNikhil H. Ramaiya. (2020) Decoding the Genomic Report for Radiologists. American Journal of Roentgenology 214:5, pages 949-961.
Crossref
Crossref
Shufeng Li, Kunpeng Jiang, Ting Wang, Wei Zhang, Minke Shi, Baojun Chen & Zichun Hua. (2020) Nanobody against PDL1. Biotechnology Letters 42:5, pages 727-736.
Crossref
Crossref
Xinran Wang & Yueping Liu. (2020) PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathology - Research and Practice 216:3, pages 152802.
Crossref
Crossref
Hui Wang, Ilana Belitskaya-Lévy & Ying Lu. 2020. Design and Analysis of Subgroups with Biopharmaceutical Applications. Design and Analysis of Subgroups with Biopharmaceutical Applications
19
31
.
Maria D. Lozano, Marta Abengozar‐Muela, José I. Echeveste, José Carlos Subtil, Juan Bertó, Alfonso Gúrpide, Alfonso Calvo & Carlos E. Andrea. (2019) Programmed death–ligand 1 expression on direct Pap‐stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Cancer Cytopathology 127:7, pages 470-480.
Crossref
Crossref